Physician profile
Peter E Levanovich
NPI 1124049358
$786.55
in general payments reported to CMS, 2019-2025
13 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $30.78 · 2022: $171 · 2023: $65.00 · 2024: $259 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $294.52 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $236.08 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $48.82 | 2023-2025 | Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.90 | 2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $25.94 | 2024 | |
| Merck Sharp & Dohme LLC | $21.93 | 2023 | Lynparza, Keytruda |
| Lundbeck LLC | $21.02 | 2024 | Rexulti |
| Janssen Biotech, INC. | $17.44 | 2024 | Akeega, Balversa, Erleada |
| Celgene Corporation | $16.25 | 2020 | |
| Amgen INC. | $15.73 | 2024 | Prolia, Evenity |
| Lilly USA, LLC | $14.55 | 2024 | Zepbound |
| Astrazeneca Pharmaceuticals Lp | $13.61 | 2019 | |
| Pfizer INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Levanovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.